| Literature DB >> 30362387 |
Dilek Canakci1, Ismail Koyuncu2, Nabih Lolak3, Mustafa Durgun4, Suleyman Akocak3, Claudiu T Supuran5.
Abstract
In this study, a series of 10 novel copper (II) and silver complexes of 1,3-diaryltriazene-substituted sulfonamides was synthesised. All the synthesised ligands and their metal complexes were assessed for in vitro cytotoxicity against human colorectal adenocarcinoma (DLD-1), cervix carcinoma (HeLa), breast adenocarcinoma (MDA-MB-231), colon adenocarcinoma (HT-29), endometrial adenocarcinoma (ECC-1), prostate cancer (DU-145 and PC-3), normal embryonic kidney (HEK-293), normal prostate epithelium (PNT-1A), and normal retinal pigment epithelium (ARPE-19) cells. Most of the metal complexes from the series showed to be more active against all cancerous cells than the uncomplexed 1,3-diaryltriazene-substituted sulfonamides, and lower cytotoxic effects observed on normal cells. Most of the Cu (II) and Ag (I) metal complexes from the presented series showed high cytotoxic activity against HeLa cells with IC50 values ranging from 2.08 to >300 µM. Specifically, compound L3-Ag showed one of the highest cytotoxicity against all cancer cell lines with IC50 values between 3.30 to 16.18 µM among other tested compounds.Entities:
Keywords: Metal complexes; cancer cells; cytotoxicity; sulfonamides; triazene
Mesh:
Substances:
Year: 2019 PMID: 30362387 PMCID: PMC6211257 DOI: 10.1080/14756366.2018.1530994
Source DB: PubMed Journal: J Enzyme Inhib Med Chem ISSN: 1475-6366 Impact factor: 5.051
Scheme 1.General binding modes of triazene ligands.
Scheme 2.General synthetic route of the novel copper (a) and silver (b) complexes.
The UV–Vis spectra data of 1,3-diaryltriazene ligands and metal complexes.
| A | B | C | D | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Compounds | |||||||||
| L1 | 233 | 0.389 | 309 | 3.289 | 360 | 3.148 | 401 | 2.637 | 3.133 |
| L2 | 260 | 3.585 | 289 | 3.937 | 366 | 2.652 | 420 | 2.792 | 2.961 |
| L3 | 254 | 1.629 | 303 | 3.547 | 360 | 3.323 | 416 | 2.949 | 2.990 |
| L4 | 254 | 1.561 | 273 | 0.486 | 341 | 1.500 | 496 | 1.442 | 2.507 |
| L5 | 255 | 2.881 | 294 | 3.730 | 341 | 1.503 | 497 | 3.374 | 2.502 |
| L1-Cu | 262 | 3.850 | 288 | 4.663 | 353 | 2.914 | 427 | 2.641 | 2.913 |
| L2-Cu | 254 | 2.294 | 303 | 3.645 | 360 | 3.399 | 461 | 4.364 | 2.698 |
| L3-Cu | 234 | 3.842 | 281 | 5.273 | 361 | 3.113 | 422 | 2.819 | 2.947 |
| L4-Cu | 260 | 1.448 | 309 | 3.142 | 363 | 3.020 | 453 | 3.145 | 2.745 |
| L5-Cu | 222 | 4.383 | 279 | 6.561 | 366 | 2.474 | 411 | 2.581 | 3.026 |
| L1-Ag | 248 | 4.537 | 287 | 5.096 | – | – | 438 | 4.104 | 2.839 |
| L2-Ag | 247 | 1.996 | 285 | 1.913 | – | – | 447 | 3.286 | 2.782 |
| L3-Ag | 268 | 3.483 | 312 | 3.529 | 359 | 3.332 | 423 | 3.177 | 2.940 |
| L4-Ag | 256 | 2.154 | 293 | 3.676 | – | – | 531 | 3.373 | 2.342 |
| L5-Ag | 259 | 2.846 | 292 | 2.540 | 367 | 2.857 | 480 | 3.509 | 2.591 |
λmax: the wavelength at the absorption maxima(nm); εmax: molar absoptivity coefficient(L/mol cm); ECT: charge transfer energy(eV).
Cytotoxicity of ligands L1-5, metal complexes of L1-5 Cu, L1-5 Ag and 5-fluorouracil (5-FU) on tumor cell lines and normal cell lines.
| Compound | IC50 (µM) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cancer cell | Normal cell | |||||||||
| DLD-1 | HeLa | MDA-MB-231 | HT-29 | ECC-1 | DU-145 | PC-3 | HEK-293 | PNT-1A | ARPE-19 | |
| L1 | 139.8 ± 11.0 | 178.8 ± 16 | 104.1 ± 28.2 | 79.4 ± 15.4 | 239.4 ± 27.5 | 29.0 ± 2.9 | 168.2 ± 18.5 | 131.7 ± 16.4 | 194.9 ± 23.5 | 279.2 ± 33.8 |
| L2 | 223.0 ± 8.3 | 768 ± 6.5 | 144.4 ± 2.4 | 265.2 ± 30 | >300 | 154.4 ± 25.6 | 170.6 ± 20.5 | 145.7 ± 13.4 | >300 | >300 |
| L3 | >300 | >300 | >300 | >300 | 197.0 ± 23.5 | 186.5 ± 20.6 | >300 | >300 | >300 | >300 |
| L4 | >300 | >300 | 155.1 ± 2.6 | >300 | >300 | 181.9 ± 23.4 | 299.4 ± 32.3 | >300 | 237.1 ± 26.8 | >300 |
| L5 | 223.6 ± 12.4 | 65.1 ± 4.5 | 144.1 ± 18.6 | 111.6 ± 16.5 | 131.6 ± 13.1 | 97.8 ± 9.7 | 131.0 ± 12.4 | 102.7 ± 10.2 | 177.4 ± 20.5 | >300 |
| L1-Cu | 47.1 ± 4.7 | 5.0 ± 0.4 | 116.8 ± 14.2 | 198.9 ± 24.3 | 26.2 ± 2.6 | 104.9 ± 13.5 | 102.0 ± 10.2 | 68.8 ± 8.7 | 76.5 ± 8.5 | 119.0 ± 13.5 |
| L2-Cu | 42.7 ± 3.3 | 2.1 ± 0.1 | 50.0 ± 2.4 | 94.9 ± 9.4 | 39.5 ± 2.5 | 116.4 ± 14.6 | 65.3 ± 8.5 | 159.2 ± 19.4 | 95.1 ± 11.1 | 131.7 ± 15.6 |
| L3-Cu | 65.2 ± 2.5 | 63.9 ± 4.3 | 48.3 ± 2.5 | 205.1 ± 20.3 | 362.1 ± 38.1 | 58.3 ± 6.4 | 196.4 ± 22.6 | 134.7 ± 15.6 | 119.5 ± 13.5 | >300 |
| L4-Cu | 58.4 ± 5.8 | 115.8 ± 9.2 | 205.5 ± 25.1 | 198.7 ± 22.5 | 307.5 ± 34.2 | 160.5 ± 18.0 | 296.8 ± 32.4 | 196.8 ± 23.5 | 125.1 ± 14.8 | 105.2 ± 13.5 |
| L5-Cu | 58.8 ± 3.9 | 15.2 ± 1.0 | 26.0 ± 2.5 | 84.4 ± 8.4 | 97.6 ± 9.7 | 32.4 ± 3.2 | 79.2 ± 8.5 | 36.3 ± 3.6 | 46.4 ± 4.6 | 84.3 ± 8.4 |
| L1-Ag | 279.3 ± 12.9 | >300 | 96.8 ± 9.6 | 185.7 ± 16.5 | 207.0 ± 25.6 | 136.7 ± 16.5 | 612.0 ± 61.2 | >300 | 209.7 ± 20.9 | >300 |
| L2-Ag | 31.6 ± 3.2 | 2.8 ± 0.1 | 30.3 ± 3.0 | 24.9 ± 2.5 | 29.1 ± 3.0 | 18.6 ± 1.8 | 28.2 ± 3.5 | 17.8 ± 1.7 | 17.5 ± 17.5 | 22.0 ± 10.2 |
| L3-Ag | 3.3 ± 0.3 | 3.4 ± 0.2 | 9.8 ± 0.9 | 10.1 ± 3.1 | 16.2 ± 1.6 | 4.8 ± 0.4 | 5.1 ± 0.5 | 9.9 ± 0.9 | 9.2 ± 0.9 | 9.5 ± 0.9 |
| L4-Ag | 173.3 ± 10.3 | 139.3 ± 28 | >300 | 240.7 ± 28.5 | 103.6 ± 10.3 | 236.7 ± 28.5 | 136.6 ± 15.8 | 5.5 ± 0.6 | 139.1 ± 16.5 | 284.8 ± 30.5 |
| L5-Ag | 110.7 ± 9.0 | 9.6 ± 0.6 | 148.4 ± 19.5 | 161.6 ± 16.1 | 135.9 ± 13.5 | 100.3 ± 10.1 | 111.7 ± 13.4 | 30.5 ± 4.5 | 110.8 ± 11.0 | 109.4 ± 11.0 |
| 5-FU | 50.2 ± 21.0 | 19.2 ± 1.2 | 22.4 ± 2.5 | 24.2 ± 2.4 | 30.6 ± 3.5 | 37.3 ± 5.8 | 45.5 ± 4.5 | 65.3 ± 8.6 | 142.3 ± 18.6 | 75.3 ± 7.5 |
Values are means of three independent experiments.
IC50 values determined at 48 h.
Figure 1.Plot of viable cells at various concentrations of L1 against DU-145 tumor cells and PNT-1A normal cell line.
Figure 2.Plot of viable cells at various concentrations of L2-Cu against HeLa tumor cells and ARPE-19 normal cell line.
Figure 3.Plot of viable cells at various concentrations of L2-Ag against HeLa tumor cells and ARPE-19 normal cell line.